Innate Pharma announces revenue for the first nine months of 2013 and updates on its cash position

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, announces revenue of 6.8 million euros for the first nine months of 2013, compared with 8.0 million euros for the same period in 2012. During the first nine months of 2013, this revenue resulted from Innate Pharma’s collaboration and licensing agreement with Bristol-Myers Squibb, signed in July 2011.

Cash, cash equivalents and current financial instruments of the Company amounted to 24.9 million euros as at September 30, 2013 including the research tax credit relating to the year 2012 (3.8 million euros) which was received in September 2013. As at September 30, 2013, the financial liabilities of the Company amounted to 3.6 million euros. Based on its current programs, the Company estimates that it has sufficient cash to fund operation into mid-2015.